MX2019005679A - Derivados de indol de utilidad como inhibidores de diacilglicerido o-aciltransferasa 2. - Google Patents
Derivados de indol de utilidad como inhibidores de diacilglicerido o-aciltransferasa 2.Info
- Publication number
- MX2019005679A MX2019005679A MX2019005679A MX2019005679A MX2019005679A MX 2019005679 A MX2019005679 A MX 2019005679A MX 2019005679 A MX2019005679 A MX 2019005679A MX 2019005679 A MX2019005679 A MX 2019005679A MX 2019005679 A MX2019005679 A MX 2019005679A
- Authority
- MX
- Mexico
- Prior art keywords
- diacylglyceride
- acyltransferase
- inhibitors
- diseases
- useful
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 150000002475 indoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 102100035762 Diacylglycerol O-acyltransferase 2 Human genes 0.000 abstract 2
- 101000930020 Homo sapiens Diacylglycerol O-acyltransferase 2 Proteins 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662424106P | 2016-11-18 | 2016-11-18 | |
| PCT/US2017/061226 WO2018093698A1 (en) | 2016-11-18 | 2017-11-13 | Indole derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019005679A true MX2019005679A (es) | 2019-08-14 |
Family
ID=62146797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019005679A MX2019005679A (es) | 2016-11-18 | 2017-11-13 | Derivados de indol de utilidad como inhibidores de diacilglicerido o-aciltransferasa 2. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10947222B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3541376B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2020500192A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190085035A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109963561A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017360941A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019009731A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3043206A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA46859A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019005679A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019117958A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018093698A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021236405A1 (en) * | 2020-05-18 | 2021-11-25 | Merck Sharp & Dohme Corp. | Novel diacylglyceride o-acyltransferase 2 inhibitors |
| EP4221703A1 (en) * | 2020-09-30 | 2023-08-09 | FL2022-001, Inc. | Hsd17b13 inhibitors and uses thereof |
| TW202229243A (zh) | 2020-10-08 | 2022-08-01 | 美商默沙東藥廠 | 作為新穎二醯基甘油酯o-醯基轉移酶2抑制劑之苯并咪唑酮衍生物的製備 |
| AR123701A1 (es) * | 2020-10-08 | 2023-01-04 | Merck Sharp & Dohme | Preparación de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 |
| EP4267135A4 (en) | 2020-12-22 | 2024-05-15 | Merck Sharp & Dohme LLC | Preparation of tetrahydroindazole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors |
| KR20250107282A (ko) | 2022-12-02 | 2025-07-11 | 머크 샤프 앤드 돔 엘엘씨 | 신규 디아실글리세리드 o-아실트랜스퍼라제 2 억제제로서의 융합된 아졸 유도체의 제조 |
| WO2024151519A2 (en) * | 2023-01-09 | 2024-07-18 | University Of Florida Research Foundatin, Incorporated | Pparg modulators |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3841520A1 (de) | 1988-12-09 | 1990-06-13 | Hoechst Ag | Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
| US5114937A (en) | 1989-11-28 | 1992-05-19 | Warner-Lambert Company | Renin inhibiting nonpeptides |
| US5095119A (en) | 1990-03-08 | 1992-03-10 | American Home Products Corporation | Renin inhibitors |
| US6054587A (en) | 1997-03-07 | 2000-04-25 | Metabasis Therapeutics, Inc. | Indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| US6284748B1 (en) | 1997-03-07 | 2001-09-04 | Metabasis Therapeutics, Inc. | Purine inhibitors of fructose 1,6-bisphosphatase |
| DE69819311T2 (de) | 1997-03-07 | 2004-07-29 | Metabasis Therapeutics Inc., San Diego | Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase |
| KR100818845B1 (ko) | 1998-09-09 | 2008-04-01 | 메타베이시스 테라퓨틱스, 인크. | 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제 |
| AU7705601A (en) | 2000-07-25 | 2002-02-05 | Merck & Co Inc | N-substituted indoles useful in the treatment of diabetes |
| EP1357908A4 (en) | 2001-01-30 | 2009-07-15 | Merck & Co Inc | "ACYLSULFAMIDES FOR THE TREATMENT OF FATIBILITY, DIABETES AND LIPID DISORDERS" |
| UY27450A1 (es) * | 2001-09-24 | 2003-04-30 | Bayer Corp | Preparación y uso de derivados de imidazol para el tratamiento de la obesidad |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| CN100457730C (zh) | 2002-08-29 | 2009-02-04 | 默克公司 | 具有抗糖尿病活性的吲哚化合物 |
| EP1546142A4 (en) | 2002-08-29 | 2007-10-17 | Merck & Co Inc | INDOLES HAVING ANTIDIABETIC EFFECT |
| AU2004207444B2 (en) | 2003-01-17 | 2008-07-31 | Merck & Co., Inc. | N-cyclohexylaminocarbonyl benzenesulfonamide derivatives |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| WO2006019831A1 (en) | 2004-07-14 | 2006-02-23 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| WO2007084413A2 (en) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| ATE531706T1 (de) | 2005-04-30 | 2011-11-15 | Boehringer Ingelheim Int | Neue piperidin-substituierte indole und ihre verwendung als ccr-3-modulatoren |
| JP4847275B2 (ja) * | 2005-10-21 | 2011-12-28 | 田辺三菱製薬株式会社 | ピラゾロ［１，５−ａ］ピリミジン化合物 |
| WO2007084435A2 (en) | 2006-01-13 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| US7514433B2 (en) | 2006-08-03 | 2009-04-07 | Hoffmann-La Roche Inc. | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives |
| AU2008205642B2 (en) | 2007-01-12 | 2013-06-06 | Msd K.K. | Spirochromanon derivatives |
| CN101743616B (zh) | 2007-06-28 | 2012-02-22 | 株式会社半导体能源研究所 | 半导体装置的制造方法 |
| CA2691010A1 (en) | 2007-06-28 | 2008-12-31 | Merck Frosst Canada Ltd. | Substituted fused pyrimidines as antagonists of gpr105 activity |
| US20110301079A1 (en) | 2007-09-21 | 2011-12-08 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Neuromedin u receptor agonists and uses thereof |
| JP2011502148A (ja) | 2007-10-31 | 2011-01-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト |
| CA2703915C (en) | 2007-10-31 | 2015-02-24 | Merck Sharp & Dohme Corp. | P2x3 receptor antagonists for treatment of pain |
| AR070398A1 (es) * | 2008-02-22 | 2010-03-31 | Gruenenthal Chemie | Derivados sustituidos de indol |
| MX2011004570A (es) | 2008-10-31 | 2011-06-17 | Merck Sharp & Dohme | Antagonistas del receptor p2x3 para el tratamiento del dolor. |
| WO2010107768A1 (en) | 2009-03-18 | 2010-09-23 | Schering Corporation | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase |
| US8569512B2 (en) * | 2009-03-23 | 2013-10-29 | Merck Sharp & Dohme Corp. | P2X3 receptor antagonists for treatment of pain |
| AU2010229142A1 (en) | 2009-03-23 | 2011-10-13 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
| WO2010111059A1 (en) | 2009-03-23 | 2010-09-30 | Merck Sharp & Dohme Corp. | P2x3 receptor antagonists for treatment of pain |
| WO2010118009A1 (en) | 2009-04-06 | 2010-10-14 | Ptc Therapeutics, Inc. | Hcv inhibitor and therapeutic agent combinations |
| KR101392334B1 (ko) * | 2011-05-03 | 2014-05-12 | 한국생명공학연구원 | 신규한 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
| EA031114B1 (ru) * | 2012-11-23 | 2018-11-30 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | ПРОИЗВОДНЫЕ ДИГИДРОПИРИМИДО[5,4-f]ОКСАЗЕПИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ДИАЦИЛГЛИЦЕРИН АЦИЛТРАНСФЕРАЗЫ |
| EP3188730B1 (en) | 2014-09-05 | 2019-05-01 | Merck Sharp & Dohme Corp. | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
| US10568876B2 (en) | 2014-09-05 | 2020-02-25 | Merck Sharp & Dohme Corp. | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 |
| WO2016036638A1 (en) | 2014-09-05 | 2016-03-10 | Merck Sharp & Dohme Corp. | Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
| JP6413032B2 (ja) | 2015-05-20 | 2018-10-24 | イーライ リリー アンド カンパニー | 新規ｄｇａｔ２阻害剤 |
-
2017
- 2017-11-13 EP EP17871875.5A patent/EP3541376B1/en active Active
- 2017-11-13 CA CA3043206A patent/CA3043206A1/en not_active Abandoned
- 2017-11-13 MX MX2019005679A patent/MX2019005679A/es unknown
- 2017-11-13 BR BR112019009731A patent/BR112019009731A2/pt not_active IP Right Cessation
- 2017-11-13 AU AU2017360941A patent/AU2017360941A1/en not_active Abandoned
- 2017-11-13 CN CN201780071481.7A patent/CN109963561A/zh active Pending
- 2017-11-13 JP JP2019526304A patent/JP2020500192A/ja not_active Ceased
- 2017-11-13 RU RU2019117958A patent/RU2019117958A/ru unknown
- 2017-11-13 MA MA046859A patent/MA46859A/fr unknown
- 2017-11-13 WO PCT/US2017/061226 patent/WO2018093698A1/en not_active Ceased
- 2017-11-13 US US16/461,880 patent/US10947222B2/en active Active
- 2017-11-13 KR KR1020197016982A patent/KR20190085035A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA3043206A1 (en) | 2018-05-24 |
| BR112019009731A2 (pt) | 2019-08-13 |
| AU2017360941A1 (en) | 2019-05-16 |
| MA46859A (fr) | 2019-09-25 |
| CN109963561A (zh) | 2019-07-02 |
| EP3541376B1 (en) | 2023-04-19 |
| US10947222B2 (en) | 2021-03-16 |
| WO2018093698A1 (en) | 2018-05-24 |
| RU2019117958A3 (cg-RX-API-DMAC7.html) | 2021-03-04 |
| KR20190085035A (ko) | 2019-07-17 |
| JP2020500192A (ja) | 2020-01-09 |
| US20190276443A1 (en) | 2019-09-12 |
| RU2019117958A (ru) | 2020-12-18 |
| EP3541376A1 (en) | 2019-09-25 |
| EP3541376A4 (en) | 2020-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019005679A (es) | Derivados de indol de utilidad como inhibidores de diacilglicerido o-aciltransferasa 2. | |
| MX2019005786A (es) | Derivados de indazol utiles como inhibidores de diacilglicerido o-aciltransferasa 2. | |
| AR065810A1 (es) | Derivados de isoindolina 4'-o-sustituidos,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer y en otros trastornos donde es necesario el control de la angiogenesis o la inhibicion de citoquinas, incluyendo tnf-alfa. | |
| WO2011051490A3 (en) | Heterocyclic derivatives | |
| WO2008086226A8 (en) | Factor xa inhibitors | |
| MX2010002675A (es) | Profarmacos para analogos de hormonas tiroideas. | |
| WO2007125405A3 (en) | Substituted 2-amino-fused heterocyclic compounds | |
| WO2014174524A8 (en) | A novel composition for nonalcoholic fatty liver disease (nafld) | |
| WO2010108074A3 (en) | Inhibitors of pi3 kinase | |
| MX2017011951A (es) | Derivados sustituidos de indol 3 novedosos, composiciones farmaceuticas y metodos para uso. | |
| WO2010105179A3 (en) | Inhibitors of beta-secretase | |
| MX2012001552A (es) | Moduladores de receptores de glutamato metabotropicos. | |
| WO2009093269A9 (en) | Novel heterocyclic compounds | |
| WO2018218044A3 (en) | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | |
| PH12019550226A1 (en) | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | |
| BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
| MX2020011225A (es) | Tetrazol que contiene inhibidores de la cinasa 1 reguladora de la señal de apoptosis y métodos de uso de los mismos. | |
| MX376202B (es) | Compuestos de tiofeno condensado utiles como inhibidores de napi-iib. | |
| WO2010132670A3 (en) | Pentacycline compounds | |
| WO2008145524A3 (en) | 4,4-disubstituted piperidine derivatives | |
| ZA202304150B (en) | Preparation of oxindole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors | |
| ZA202304148B (en) | Preparation of benzimidazolone derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors | |
| AU2017297550A8 (en) | Pyrrolidine derivative serving as PPAR agonist | |
| MX2009004982A (es) | Derivados heterociclicos como inhibidores cetp. | |
| NZ707832A (en) | 2-pyridone compound |